Sign in or create a free account to view this dataset's chart and data table.
Key Takeaway
- Respiratory system medicines recorded a CAGR of 0% between FY 2019–20 and FY 2024–25, indicating broadly stable sales. The category includes expectorants, mucolytics, decongestants, bronchodilators and respiratory stimulants. Its performance contrasts with the stronger growth recorded in immunotherapy and several other therapeutic categories.
About This Dataset
Annual sales data for animal health respiratory system medicines, including expectorants, mucolytics, decongestants, bronchodilators and respiratory stimulants. These products are used to manage respiratory symptoms and support respiratory function in animals. The dataset presents aggregated sales by financial year from 1 July to 30 June.
Methodology
Sign in or create a free account to view this dataset's methodology and sources.
Available formats: Excel, CSV, PNG, PDF.
Transform Data Into Better Business Decisions
Join organizations that rely on statSCALAR for trusted market intelligence, industry statistics, commodity insights and enterprise research.